- ICH GCP
- US Clinical Trials Registry
- Search trials
Clinical Trials on EGFR Mutated EGFR TKI Naive Metastatic NSCLC in Belgium
Total 4 results
-
AmgenActive, not recruitingKRAS p, G12c Mutated /Advanced Metastatic NSCLCFinland, United States, Canada, Belgium, Spain, Korea, Republic of, Netherlands, United Kingdom, Australia, Denmark, Hungary, Sweden, Taiwan, Greece, Russian Federation, Switzerland, France, Italy, Japan, Poland, Brazil, Germany, Po...
-
Merck KGaA, Darmstadt, GermanyCompletedEpidermal Growth Factor Receptor (EGFR) Expressing Metastatic Colorectal CancerSweden, Australia, Brazil, Bulgaria, France, Italy, Korea, Republic of, Russian Federation, South Africa, Spain, Turkey, United Kingdom, Germany, Hungary, Poland, Romania, Austria, Belgium, Finland, Netherlands, Slovakia, Greece, Ta... and more
-
Novartis PharmaceuticalsActive, not recruitingLocally Advanced or Metastatic KRAS G12C-mutated NSCLC With a PD-L1 Expression <1% or a PD-L1 Expression ≥ 1% and an STK11 Co-mutationSpain, Italy, Austria, Netherlands, United Kingdom, Germany, Thailand, France, Belgium, China, Argentina, Greece, Turkey, Malaysia, Portugal, Hungary, Brazil, United States, India
-
AstraZenecaParexelActive, not recruitingLocally Advanced or Metastatic EGFR Sensitising Mutation Positive Non Small Cell Lung CancerBelgium, United States, Canada, Poland, Romania, Taiwan, Thailand, Vietnam, France, Italy, Korea, Republic of, Brazil, Japan, Turkey, China, Malaysia, Germany, Spain, Australia, Hungary, Portugal, Switzerland, Israel, Philippines, Russian... and more